BIOCHEMICAL CORE
BIOCHEMICAL CORE
批准号:
8025974
负责人:
TODD W VANDERAH
金额:
$36.91万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2014-03-31
关键词:
AchievementAcuteAcute PainAffinityAgonistAnimal ModelAnimalsAreaBehavioralBindingBinding SitesBiochemicalBiologicalBiological AssayBradykininBradykinin B2 ReceptorBradykinin ReceptorCalciumCalcium ChannelCaviaCellsCharacteristicsChemistryChronicChronic inflammatory painComplementary DNAComplexDataData AnalysesDoseDyesDynorphin ADynorphinsEnkephalin, Ala(2)-MePhe(4)-Gly(5)-EnsureEquipmentEvaluationExhibitsFeedbackFluo-3GoalsHumanHuman ResourcesHyperalgesiaHypersensitivityIACUCIn VitroInflammatoryInhibitory Concentration 50KallidinLabelLeadLigationMaintenanceMeasuresMechanicsMediatingMedicalModelingMusNaloxoneNarcotic AntagonistsNegative ReinforcementsNeuropathyOpiatesOpioidOpioid ReceptorPainPathologyPotassium ChlorideProtocols documentationQuality of lifeRadiationRadiolabeledRattusReaction TimeRegulationRouteScreening procedureSensory ThresholdsSignal TransductionSpinal nerve structureStimulusStructure-Activity RelationshipTailTestingTissuesTrainingVas deferens structureWithdrawalanalogbasechronic neuropathic painchronic paindeltorphindesigndrug discoveryfluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl etherileumin vitro Assayin vitro Bioassayin vitro activityin vivoin vivo Modelmeetingsnovelnovel strategiespainful neuropathypreventprogramsradiotracerreceptorreceptor bindingsubcutaneousvoltage
中文摘要
点击翻译按钮获取中文摘要
英文摘要
by
the Chemistry Core. These compounds will be designed as opioid agonists and bradykinin/dynorphin
antagonists in order to produce potent and efficacious antinociception targeting the pathology of neuropathic
pain while eliminating antinocicpetive tolerance.
The Biochemical Core contains 7 aims that will test such novel compounds. The in vitro pharmacological
data in particular will provide timely feedback to the Chemistry Core on the structure-activity relationship
(SAR) to further inform chemistry design. The initial binding and functional characterization of all novel
compounds (est. 20 to 50 compounds/year) is necessary and essential for target-based drug discovery. To
identify lead compounds, we must evaluate their affinity at multiple opioid and bradykinin receptors, and their
apparent biological activity at each of these receptors. Studies will include in vitro tissue assaysto determine
agonist and antagonist activity as well as novel compound activity at calcium channles using calcium
fluorimetric analysis in transfectd cells. We will use a number of in vivo animal models to identify whether
such novel bi-functional compounds produce antinociception as well as antihyperalgesia in inflammatory and
chronic pain states. Finally, in vivo studies will be performed to detemine whether such compounds will
result in antinocicpetive tolerance. Overall, Studies will be performed to identify molecules with agonist
activity at one receptor and concurrent antagonist actions at a second receptor. The biochemical core
provides dedicated equipment, personnel and expertise in data analysis for the entire project. It serves to
centralize the use and maintenance of shared equipment and the technical training of personnel to use these
equipment, management and oversight of animal protocols required by IACUC and Radiation Control, as
well as to ensure data and information sharing with the Chemistry Core and the other projects. The
biochemical core will synergize with projects A, C and D by providing lead compounds to directly test their
hypotheses.
RELEVANCE (Seeinstructions):
Inflammatory and chronic neuropathic pains are growing areas of unmet medical need. Clinically, chronic
pain remains poorly controlled by available therapies and thus adversely impacts quality of life (Arner &
Meyerson, 1988). One reason for this lack of effect is the absence of compounds that specifically target the
pathology of neuropathic pain. The goal of the chemistry & biochemical core of this PPG are to synthesize
and test compounds that result in potent and efficacious antinociception while eliminating tolerance.
PROJECT/
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:8606826
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:8212471
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:8665531
-
项目类别:
-
资助金额:$4.54万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:8790836
-
项目类别:
-
资助金额:$5.29万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:8034209
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:8444336
-
项目类别:
-
资助金额:$28.37万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
-
批准号:7884774
-
项目类别:
-
资助金额:$31.11万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain
-
批准号:9329913
-
项目类别:
-
资助金额:$35.05万
-
财政年份:2010
-
负责人:TODD W VANDERAH
-
依托单位:
Brain Stem Mechanisms of Opioid Induced Pain
-
批准号:7385881
-
项目类别:
-
资助金额:$9.83万
-
财政年份:2005
-
负责人:TODD W VANDERAH
-
依托单位:
Brain Stem Mechanisms of Opioid Induced Pain
-
批准号:7215275
-
项目类别:
-
资助金额:$9.54万
-
财政年份:2005
-
负责人:TODD W VANDERAH
-
依托单位:
Brain Stem Mechanisms of Opioid Induced Pain
-
批准号:6853014
-
项目类别:
-
资助金额:$8.96万
-
财政年份:2005
-
负责人:TODD W VANDERAH
-
依托单位:
Brain Stem Mechanisms of Opioid Induced Pain
-
批准号:7031029
-
项目类别:
-
资助金额:$9.27万
-
财政年份:2005
-
负责人:TODD W VANDERAH
-
依托单位:
Brain Stem Mechanisms of Opioid Induced Pain
-
批准号:7579928
-
项目类别:
-
资助金额:$10.12万
-
财政年份:2005
-
负责人:TODD W VANDERAH
-
依托单位:
RVM CCK, Pain, and Opioid Tolerance
-
批准号:7061625
-
项目类别:
-
资助金额:$18.49万
-
财政年份:2002
-
负责人:TODD W VANDERAH
-
依托单位:
RVM CCK, Pain, and Opioid Tolerance
-
批准号:6751703
-
项目类别:
-
资助金额:$26.51万
-
财政年份:2002
-
负责人:TODD W VANDERAH
-
依托单位:
RVM CCK, Pain, and Opioid Tolerance
-
批准号:6623320
-
项目类别:
-
资助金额:$26.51万
-
财政年份:2002
-
负责人:TODD W VANDERAH
-
依托单位:
RVM CCK, Pain, and Opioid Tolerance
-
批准号:6878952
-
项目类别:
-
资助金额:$17.85万
-
财政年份:2002
-
负责人:TODD W VANDERAH
-
依托单位:
RVM CCK, Pain, and Opioid Tolerance
-
批准号:6464763
-
项目类别:
-
资助金额:$28.39万
-
财政年份:2002
-
负责人:TODD W VANDERAH
-
依托单位:
CLONING & EXPRESSION OF A DELTA OPIOID RECEP SUBTYPE
-
批准号:2117977
-
项目类别:
-
资助金额:$0.43万
-
财政年份:1995
-
负责人:TODD W VANDERAH
-
依托单位:
CLONING & EXPRESSION OF A DELTA OPIOID RECEP SUBTYPE
-
批准号:2117976
-
项目类别:
-
资助金额:$1.3万
-
财政年份:1994
-
负责人:TODD W VANDERAH
-
依托单位:
海外基金